April 18th, 2013
Advice for Physicians: How to Behave Online
Larry Husten, PHD
Although the internet represents “a new frontier in medicine” for physicians and patients, it also presents numerous and novel challenges to professionalism, according to a position paper from the American College of Physicians and the Federation of State Medical Boards published in the Annals of Internal Medicine.
The paper offers physicians a new conceptual “framework for analyzing medical ethics and professionalism issues” on the internet and provides recommendations for physicians on the use of email, blogs, social media sites, and more.
Although there are numerous valuable educational resources available, the authors advise physicians to evaluate the quality of online content before giving recommendations to their patients. Physicians who use blogs, Twitter, and other outlets to vent against patients are “disrespectful” and may “undermine trust in the profession.”
The paper also discusses the problem of confidentiality in the digital age and maintaining security on mobile devices.
The authors recommend that physicians maintain clear and distinct professional and social identities online, but professional standards must be maintained in both spheres. Patients should not be “friended” by physicians and should not be included in the personal or social online interactions of physicians. The authors also advise physicians and physicians-in-training that medical humor, though intended for fellow professionals, can easily find a wider audience on the internet.
Categories: General
Tags: American College of Physicians, online behavior, professionalism, social media
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
-
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel.
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI November 19, 2026Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months.
- Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke November 19, 2026In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time...
- Too Soon to Say Goodbye — Aspirin at the Door in STEMI November 19, 2026The 19th-century English biologist Thomas H. Huxley once said, “The great tragedy of Science — the slaying of a beautiful hypothesis by an ugly fact.” For as long as many can recall, aspirin has been the first drug administered for the treatment of ST-segment elevation myocardial infarction (STEMI), often in...
- Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke November 19, 2026Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy.
- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
